This week we are headed to the University of Maryland in College Park, Maryland, for the TRTR and IGORR Research Reactor Conference.
Dr. Sarah Jones, Vice President of Serva Medical, will speak as part of a panel discussion on industry collaborations.
She will present on Serva’s reactor-based method for producing Actinium-225 (Ac-225) and Serva's ability to scale rapidly through strategic partnerships.
“I’m really looking forward to engaging with this panel and connecting with colleagues around medical isotopes and Ac-225,” said Dr. Jones. “There’s so much happening in this field right now, and there's so much to learn. It’s exciting.”
Serva is leveraging nuclear technology in the development of novel production methods able to dramatically increase the supply of rare medical isotopes, including Ac-225.